pI: 8.72 |
Length (AA): 663 |
MW (Da): 77219 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 11 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
294 | 419 | 1n52 (B) | 16 | 144 | 17.00 | 0.0000000023 | 1 | 0.53 | -1.13 |
315 | 391 | 1h2v (Z) | 37 | 116 | 25.00 | 0.0000000024 | 1 | 0.67 | -2.5 |
468 | 662 | 2adc (A) | 340 | 531 | 24.00 | 0 | 1 | 0.59 | -0.89 |
576 | 657 | 1oo0 (B) | 66 | 148 | 23.00 | 0.000000074 | 1 | 0.63 | -2.04 |
315 | 411 | 2adb (A) | 181 | 276 | 45.00 | 0.000000000022 | 1 | 0.779305 | -1 |
466 | 662 | 2adc (A) | 338 | 531 | 28.00 | 0.000000000055 | 1 | 0.725134 | -0.85 |
581 | 660 | 3egn (A) | 418 | 503 | 23.00 | 0.037 | 1 | 0.526164 | -1.81 |
314 | 410 | 2adb (A) | 181 | 276 | 45.00 | 0.000000000022 | 1 | 0.779326 | -1 |
457 | 657 | 4qpt (A) | 372 | 574 | 21.00 | 0.00000043 | 1 | 0.611825 | -0.49 |
582 | 656 | 1p27 (B) | 73 | 148 | 25.00 | 0.027 | 1 | 0.598493 | -1.76 |
585 | 654 | 1whw (A) | 41 | 111 | 23.00 | 0.18 | 0.95 | 0.51994 | -1.3 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, Ring. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 24 hs, Oocyst, Male Gametocyte. | Otto TD Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, Sporozoite, Female Gametocyte. | Otto TD Zanghi G Lasonder E |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Ortholog group members (OG5_127719)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G43190 | polypyrimidine tract-binding protein 3 |
Brugia malayi | Bm1_11305 | hypothetical protein |
Caenorhabditis elegans | CELE_D2089.4 | Protein PTB-1, isoform A |
Dictyostelium discoideum | DDB_G0284321 | RNA recognition motif-containing protein RRM |
Drosophila melanogaster | Dmel_CG31000 | hephaestus |
Echinococcus granulosus | EgrG_000614400 | Regulator of differentiation 1 |
Echinococcus multilocularis | EmuJ_000614400 | Regulator of differentiation 1 |
Homo sapiens | ENSG00000117569 | polypyrimidine tract binding protein 2 |
Homo sapiens | ENSG00000119314 | polypyrimidine tract binding protein 3 |
Homo sapiens | ENSG00000011304 | polypyrimidine tract binding protein 1 |
Leishmania braziliensis | LbrM.04.1190 | RNA-binding protein, putative |
Leishmania braziliensis | LbrM.32.0940 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_041190.1 | Double RNA binding domain protein 3 |
Leishmania donovani | LdBPK_320900.1 | polypyrimidine tract-binding protein, putative |
Leishmania infantum | LinJ.04.1190 | RNA-binding protein, putative |
Leishmania infantum | LinJ.32.0900 | hypothetical protein, conserved |
Leishmania major | LmjF.04.1170 | RNA-binding protein, putative |
Leishmania major | LmjF.32.0850 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.04.1170 | RNA-binding protein, putative |
Leishmania mexicana | LmxM.31.0850 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_11032 | hypothetical protein |
Loa Loa (eye worm) | LOAG_13430 | hypothetical protein |
Loa Loa (eye worm) | LOAG_14331 | hypothetical protein |
Loa Loa (eye worm) | LOAG_14332 | hypothetical protein |
Loa Loa (eye worm) | LOAG_15376 | hypothetical protein |
Mus musculus | ENSMUSG00000028382 | polypyrimidine tract binding protein 3 |
Mus musculus | ENSMUSG00000028134 | polypyrimidine tract binding protein 2 |
Mus musculus | ENSMUSG00000006498 | polypyrimidine tract binding protein 1 |
Neospora caninum | NCLIV_042650 | GG11844, related |
Oryza sativa | 4338905 | Os05g0437300 |
Oryza sativa | 4325048 | Os01g0867800 |
Onchocerca volvulus | OVOC9716 |
|
Plasmodium berghei | PBANKA_0105200 | polypyrimidine tract-binding protein, putative |
Plasmodium falciparum | PF3D7_0606500 | polypyrimidine tract-binding protein, putative |
Plasmodium knowlesi | PKNH_1143700 | polypyrimidine tract-binding protein, putative |
Plasmodium vivax | PVX_113495 | polypyrimidine tract binding protein, putative |
Plasmodium yoelii | PY01048 | neural polypyrimidine tract binding protein |
Schistosoma japonicum | Sjp_0120680 | expressed protein |
Schistosoma japonicum | Sjp_0208600 | Regulator of differentiation 1, putative |
Schistosoma japonicum | Sjp_0099930 | Polypyrimidine tract-binding protein 1, putative |
Schistosoma mansoni | Smp_036590.2 | polypyrimidine tract binding protein |
Schistosoma mansoni | Smp_138050.2 | polypyrimidine tract binding protein |
Schistosoma mansoni | Smp_138050.1 | polypyrimidine tract binding protein |
Schmidtea mediterranea | mk4.033658.00 | |
Schmidtea mediterranea | mk4.017830.01 | |
Schmidtea mediterranea | mk4.002486.04 | |
Schmidtea mediterranea | mk4.025262.00 | FI03683p |
Schmidtea mediterranea | mk4.001622.05 | |
Schmidtea mediterranea | mk4.035163.00 | |
Schmidtea mediterranea | mk4.001622.06 | |
Schmidtea mediterranea | mk4.002647.00 | |
Schmidtea mediterranea | mk4.013283.01 | |
Schmidtea mediterranea | mk4.012260.00 | |
Schmidtea mediterranea | mk4.001628.07 | |
Schmidtea mediterranea | mk4.007390.00 | |
Trypanosoma brucei gambiense | Tbg972.9.4840 | RNA-binding protein, putative,DRBD4 |
Trypanosoma brucei gambiense | Tbg972.11.15740 | RNA-binding protein, putative,DRBD4 |
Trypanosoma brucei | Tb927.9.8740 | Double RNA binding domain protein 3 |
Trypanosoma brucei | Tb927.11.14100 | Double RNA-binding domain containing protein 4 |
Trypanosoma congolense | TcIL3000.11.14390 | polypyrimidine tract-binding protein, putative |
Trypanosoma congolense | TcIL3000_9_3060 | Double RNA binding domain protein 3 |
Trypanosoma cruzi | TcCLB.506649.80 | Double RNA binding domain protein 3 |
Trypanosoma cruzi | TcCLB.511727.160 | polypyrimidine tract-binding protein, putative |
Toxoplasma gondii | TGME49_290660 | RNA recognition motif-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.0560 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.0560 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.0560 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.211.0560 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb11.01.5690 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.5690 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.5690 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.01.5690 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_0105200 | Plasmodium berghei | Dispensable | plasmo |
TGME49_290660 | Toxoplasma gondii | Probably essential | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | polypyrimidine tract binding protein 1 | Compounds | References |